How to Buy Macrogenics Stock
Macrogenics Inc
MacroGenics, Inc. , a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States.
Macrogenics stock last closed at $3.45, up 6.15% from the previous day, and has decreased 36.35% in one year. It has underperformed other stocks in the Biotechnology industry by 0.29 percentage points. Macrogenics stock is currently +9.87% from its 52-week low of $3.14, and -84.23% from its 52-week high of $21.88.
As of Sep 9, 2024, there are 62.72M shares of MGNX outstanding. The market cap of MGNX is $216.39M. In the last 24 hours, 1.75M MGNX shares were traded.
How to Buy Macrogenics Stock
Wondering how to invest in Macrogenics stock? Here's how.
- Figure out where to buy Macrogenics stock: You need to choose a stock brokerage, but don't worry - we've tested dozens of stock brokerages and apps to help you figure out where to buy Macrogenics stock.
- Create your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Put funds into your investment account: Choose your payment method and add your details.
- Evaluate Macrogenics stock: The Macrogenics ticker symbol is MGNX. Is Macrogenics stock a good investment? Should you buy shares of MGNX? How do MGNX's underlying business fundamentals look? Do top analysts think Macrogenics is a good buy? Why has MGNX's stock price moved recently? (Hint: Our stock market research tools can help you figure out if MGNX is a good stock to buy).
- Execute your MGNX trade: Decide if you will purchase MGNX shares at the current market price or use a limit order to buy MGNX shares at a specific price.
- Keep an eye on your MGNX investment: Create a watchlist to monitor your new investment in Macrogenics stock.
Step 1: Figure out where to buy Macrogenics stock
You will need a brokerage account in order to access the NASDAQ market and buy MGNX shares.
Our preferred brokerage: eToro
Based on our analysis, eToro is the best online stock brokerage. Here's why:
- You can invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
- Access to global financial markets: From Tech to Utilities, New York to Hong Kong — you can fill your portfolio with stocks from the world's top stock exchanges.
- Social investing: eToro offers a community with more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by opening an account with eToro now.
Open eToro AccountStep 2: Create your brokerage account
Now that you've chosen the best brokerage, you need to fill out some personal info so you can buy MGNX today.
How to Create a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal info to start a new trading account.
- Send your information by clicking the "Create Account" button. Get started with eToro today
Step 3: Put funds into your investment account
Now that you've filled out your info on apps for stock market, your next step is to transfer the money for your investment:
Check out this video walkthrough to see the process of depositing money into your brokerage account.
Step 4: Evaluate Macrogenics stock
After you have selected the best place to buy Macrogenics stock, it's very important to research their stock prior to investing, so you truly comprehend the risk as well as the opportunity.
Overview of key MGNX info
MGNX Overview
WallStreetZen was designed to help everyday investors perform more accurate fundamental analysis.
You can see all of the due diligence checks on MGNX's stock page.
How is MGNX stock valued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge MGNX's true value.
Using relative valuations methods:
- MGNX could be undervalued based on its P/B ratio of 3.74x, relative to Biotechnology industry P/B ratio of 6.32x
You can access additional valuation analysis on MGNX's stock here.
MGNX Financial Health Overview
Positive Health Checks:
- There are more short-term assets than long-term liabilities on the MGNX balance sheet.
- There are more short-term assets than short-term liabilities on the MGNX balance sheet.
Negative Health Checks:
- MGNX has cash burn of 156934000. It does not have sufficient cash and short-term investments to cover this.
- MGNX has a relatively high debt to equity ratio of 2.48.
- MGNX profit margin has gone down from 4.9% to -332.5% in the past year.
- Total MGNX debt is higher than 5 years ago, relative to shareholder equity.
- MGNX has $140.37M in cash and short term investments. This is not enough to cover its annual cash burn of $156.93M.
Do analysts think it's a good time to buy Macrogenics stock
Out of 8 Equities analysts who research MGNX, the consensus analyst rating on Macrogenics is a Buy
It's important to keep in mind that analyst forecasts are not stock recommendations, nor are they financial advice.
Most Recent MGNX Analyst Upgrades/Downgrades
Mayank Mamtani, a top 2% analyst from B. Riley Securities downgrades MGNX to a hold rating and lowers their MGNX price target from $18.00 to $5.00, on Jul 31, 2024.
Kaveri Pohlman, a bottom 10% analyst from BTIG maintains MGNX with a strong buy rating and lowers their MGNX price target from $24.00 to $9.00, on May 24, 2024.
Stephen Willey, a bottom 3% analyst from Stifel Nicolaus downgrades MGNX to a hold rating and lowers their MGNX price target from $29.00 to $7.00, on May 10, 2024.
You can dive deeper into what analysts are projecting on the Macrogenics stock forecast page.
Metrics for Advanced MGNX Traders
MGNX Performance Numbers
Last year, MGNX revenue was $41.02M. In the last 5 year, MGNX's revenue has gone up by -6.32% per year. This was slower than the Biotechnology industry average of 57.69%.
Find out more about MGNX's earnings and revenue performance here.
What are MGNX insiders up to?
Over the past 12 months, executives and large shareholders at MGNX have sold more shares than they have bought.
Jeffrey Stuart Peters, Senior VP and General Counsel of MGNX, was the latest MGNX insider to sell. They sold $57,666.30 worth of MGNX stock on Apr 4, 2024.
Learn more about who owns MGNX stock here.
Can I get consistent income from MGNX stock?
No, Macrogenics doesn't provide an income stream by paying out dividends.
Get opinions from other traders
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Execute your MGNX trade
There are two main order types:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are usually fine for most investors. - Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at a particular dollar amount limit, place a limit order.
Click the Open button and your broker will place the order.
If you need additional help with buying stocks on eToro, click the helpful video below:
Step 6: Keep an eye on your MGNX investment
Now that you own some MGNX stock, you'll want to keep up with your new investment.
Put MGNX on a watchlist to get notified of important updates regarding your MGNX stock.
MGNX Feed
How to Buy Stock in Macrogenics
To reiterate, here are the 6 steps to buy stock in Macrogenics:
- Figure out where to buy Macrogenics stock
- Create your brokerage account
- Put funds into your investment account
- Evaluate Macrogenics stock
- Execute your MGNX trade
- Keep an eye on your MGNX investment
If you need a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you would like to keep an eye on your new investment in Macrogenics, get started below.
More Content You May Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.